Jump to Header Jump to Main Content Jump to Footer

trials found matching your search:


Displaying 20 of 280 Results
Age
Type
Conditions or Disease:

PhI/II DosEscalDosExpan&CohortExpanFMC376 Particip w/KRASG12C MutatLocalAdvUnresec orMetsSolidTu

Farshid Dayyani

  • OPEN TO ACCRUAL

PhIMeninInhibitorSNDX-5613ComboW/Daunorubicin&CytarabineNewDxPtsW/AcuteMyeloidLeukemia&NPM1

Kiran Naqvi

  • OPEN TO ACCRUAL

PhII Study Amivantamab EGFR or MET- Amplified Esophagogastric Ca

Farshid Dayyani

  • OPEN TO ACCRUAL

PhII EvalEfficSaf&Impact TuMicroen CombTocilizumabAtezolizumab&FractioStereotac Radiothe Recur Gliob

Xiao-Tang Kong

  • OPEN TO ACCRUAL

PhIITriapine+Lutetium177DotatatVsLutetium177DotatAloneWellDifferentiatSomatostatinRecept+NeuroendoTu

Farshid Dayyani

  • OPEN TO ACCRUAL

Lutikizumab for Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

Sandra Park

  • OPEN TO ACCRUAL

ParalPhIIIRandTriGenomicRiskStratifiedUnfavInterRisProstaCaDeIntensific&IntensificClinTriEvaluGUIDAN

David Hong

  • OPEN TO ACCRUAL

PhIbDosEscaPhIIDosOptOralZongertinibCombw/IntravenT-DXdCombw/IntraT-DM1 TxPaw/AdvHER2+mBC&mGEAC

Farshid Dayyani

  • OPEN TO ACCRUAL

Efficacy & Safety of CG-100 Intraluminal Bypass Device in Colorectal & Coloanal Anastomoses

Joseph Carmichael

  • OPEN TO ACCRUAL

RandomPhIIStudy CabozantinibIpilimumab&Nivolumab Pa w/SoftTissue Sarcoma

Warren A Chow

  • OPEN TO ACCRUAL

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females with Obstetric Injury (Dign

Joseph Carmichael

  • OPEN TO ACCRUAL

ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with CKD from CSA-AKI and MAKE

Jack Sun

  • OPEN TO ACCRUAL

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People with ALS

Namita Goyal

  • OPEN TO ACCRUAL

JanusRectalCancerTrial: PhII TripletVSDoublet ChemoClinicalComplete Response Pa w/LocallyAdvRectalCa

Jason Zell

  • OPEN TO ACCRUAL

A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS or PMS

Michael Sy

  • OPEN TO ACCRUAL

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimer

Priyanka Iyer

  • OPEN TO ACCRUAL

Evaluate Safety of a Single Intravitreal Injection of RTx-015 in Patients with Retinitis Pigmentosa

Baruch Kuppermann

  • OPEN TO ACCRUAL